



PIPER RUDNICK LLP
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 5398-001-27

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/675,979
Applicant(s): Limin LI
Filing Date: October 1, 2003
For: ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT
OF VIRAL INFECTION
Group Art Unit: 1645
Examiner:

SIR:

Attached hereto for filing are the following papers:

Information Disclosure Statement
List of Related Cases
PTO-1449
Cited References (27)

Our check in the amount of \$ 0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP

Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Michael Ye
Registration No.: 47,195

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Ljimin LI

GROUP ART UNIT: 1645

SERIAL NUMBER: 10/675,979

EXAMINER:

FILED: October 1, 2003

FOR: ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents. Documents BN - BT will be provided at a later date.

RELATED CASES

- Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:


- ☐ without fee and within three months of the filing date of the application.
- ☐ without fee and within three months of the date of entry of the U.S. national stage.
- without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- ☐ without fee and with the appropriate certification above.
- ☐ without fee and with a new CPA application.
- ☐ without fee and with a Request for Continued Examination.
- ☐ with fee and before the mailing date of any Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- ☐ with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,


PIPER RUDNICK LLP


Steven B. Kelber

Attorney of Record
Registration No. 30,073
Michael Ye
Registration No. 47,195

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

DOCKET NO.: 5398-001-27




LIST OF RELATED CASES

Docket Number	Serial or Patent Number	Filing or Issue Date	Status or Patentee
*5398-001-27	10/675,979	October 1, 2003	Pending
5398-026-27 CONT	09/804,690	March 12, 2001	Pending

The cases listed on this Notice of Related Cases include cases which may contain information that is material to patentability. The listing of a case on this Notice should not be taken as an indication or admission that any information contained therein is material. Prior art for each case listed on this Notice may have been cited. **The files corresponding to the listed cases, which are available to the Examiner, may not have not been examined to ascertain the materiality of any prior art therein.** Accordingly, the Examiner is requested to review the file for each case listed on this Notice in order to assess the materiality of such prior art.

*Present application; listed for information.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 5398-001-27		SERIAL NO. 10/675,979	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Limin LI			
				FILING DATE October 1, 2003		GROUP ART UNIT 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2002/0177207	11/28/02	SUGIYAMA, et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	AB	WO 02/072790	09/19/02	WIPO		X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AC	Oh, et al., "Negative regulation of cell growth and differentiation by TSG101 through association with p21 ^{Cip1/WAF1} , Proc. Natl. Acad. Sci. USA, Vol. 99, No. 8, pp. 5430-5435, 2002.					
	AD	Krempler, et al., "Targeted Deletion of the <i>Tsg101</i> Gene Results in Cell Cycle Arrest at G ₁ /S and p53-independent Cell Death", Jour. Biol. Chem., Vol. 277, No. 45, pp. 43216-41223, 2002.					
	AE	Wagner, et al., "Tsg101 Is Essential for Cell Growth, Proliferation, and Cell Survival of Embryonic and Adult Tissues", Mol. and Cell Biol., Vol. 23, No. 1, pp. 150-162, 2003.					
	AF	Bishop, et al., "Mammalian cell E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates", Jour. Cell Biol., Vol. 157, No. 1, pp. 91-101, 2002.					
	AG	Li, et al., "A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control", Proc. Natl. Acad. Sci. USA, Vol. 98, No. 4, pp. 1619-1624, 2001.					
	AH	Ruland, et al., "p53 Accumulation, defective cell proliferation, and early embryonic lethality in mice lacking <i>tsg101</i> ", Proc. Natl. Acad. Sci. USA, Vol. 98, No. 4, pp. 1859-1864, 2001.					
	AI	Moyret-Lalle, et al., "p53 Induction Prevents Accumulation of Aberrant Transcripts in Cancer Cells", Cancer Research, Vol. 61, pp. 486-488, 2001.					
	AJ	Göttlinger, et al., "Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 3195-3199, 1991.					
	AK	Huang, et al., "p6 ^{Gag} Is Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease", Jour. Virol., Vol. 69, No. 11, pp. 6810-6818, 1995.					
	AL	Parent, et al., "Positionally Independent and Exchangeable Late Budding Functions of the Rous Sarcoma Virus and Human Immunodeficiency Virus Gag Proteins", Jour. Virol. Vol. 69, No. 9, pp. 5455-5460, 1995.					
	AM	Yuan, et al., "Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle", The EMBO Jour., Vol. 18, No. 17, pp. 4700-4710, 1999.					
EXAMINER					DATE CONSIDERED		
<p>*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>							

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 5398-001-27	SERIAL NO. 10/675,979
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Limin LI	
		FILING DATE October 1, 2003	GROUP ART UNIT 1645
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
BA	Yasuda, et al., "A Proline-Rich Motif (PPPY) in the Gag Polyprotein of Mason-Pfizer Monkey Virus Plays a Maturation-Independent Role in Virion Release", Jour. Virol. Vol. 72, No. 5, pp. 4095-4103, 1998.		
BB	Puffer, et al., "Equine Infectious Anemia Virus Utilizes a YXXL Motif within the Late Assembly Domain of the Gag p9 Protein", Jour. Virol., Vol. 71, No. 9, pp. 6541-6546, 1997.		
BC	Wills, et al., "An Assembly Domain of the Rous Sarcoma Virus Gag Protein Required Late in Budding", Jour. Virol., Vol. 68, No. 10, pp. 6605-6618, 1994.		
BD	VerPlank, et al., "Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55 ^{Gag} ", Proc. Natl. Acad. Sci. USA, Vol. 98, No. 14, pp. 7724-7729, 2001.		
BE	Garrus, et al., "Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding", Cell, Vol. 107, pp. 55-65, 2001.		
BF	Martin-Serrano, et al., "HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress", Nature Medicine, Vol. 7, No. 12, pp. 1313-1319, 2001.		
BG	Pornillos, et al., "Structure and functional interactions of the Tsg101 UEV domain", The EMBO Jour., Vol. 21, No. 10, pp. 2397-2406, 2002.		
BH	Demirov, et al., "Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function", Proc. Natl. Acad. Sci. USA, Vol. 99, No. 2, pp. 955-960, 2002.		
BI	Patnaik, et al. "Ubiquitin is part of the retrovirus budding machinery", Proc. Natl. Acad. Sci. USA, Vol. 97, No. 24, pp. 13069-13074, 2000.		
BJ	Schubert, et al., "Proteasome inhibition interferes with Gag polyprotein processing, release, and maturation of HIV-1 and HIV-2", Proc. Natl. Acad. Sci. USA, Vol. 97, No. 24, pp. 13057-13062, 2000.		
BK	Strack, et al., "A role for ubiquitin ligase recruitment in retrovirus release", Proc. Natl. Acad. Sci. USA, Vol. 97, No. 24, pp. 13063-13068, 2000.		
BL	Bishop, et al., "TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly and Are Recruited to VPS4-induced Endosomes", Jour. Cell Biol., Vol. 276, No. 15, pp. 11735-11742, 2001.		
BM	Little, et al., "Antiretroviral-Drug Resistance Among Patients Recently Infected With HIV", New. Eng. Jour. Med., Vol. 347, No. 6, pp. 385-394, 2002.		
BN	Li, et al., Cell, Vol. 85, pp. 319-320, 1996.		
BO	Zhong, et al., Cancer Research, Vol. 58, pp. 2699-2702, 1998.		
BP	Babst, et al., Traffic, Vol. 1, pp. 248-258, 2000.		
BQ	Wills, et al., Aids, Vol. 5, pp. 639-654, 1991.		
BR	Blower, et al., AIDS Rev., Vol. 5, pp. 113-125, 2003.		
BS	Valdiserri, et al., Nat. Med., Vol. 9, pp. 881-886, 2003.		
BT	Thali, et al., J. Acquired Immune Deficiency Syndromes, Vol. 5, pp. 591-599, 1992.		
EXAMINE		DATE CONSIDERED	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			